UTGL Donates HK$650,000 to Advance Anti-Aging, Cardiovascular Health and Healthy Longevity Through Corporate Social Responsibility and Clinical Research

UniTrust Global Limited (UTGL) announced a HK$650,000 donation to Prime Healthcare Medical Services Limited to support a clinical study on Enhanced External Counterpulsation (EECP). The research, titled *Efficacy and Dose-Response of Enhanced External Counterpulsation (EECP) on Blood Pressure in Pre-hypertension and Stage 1 Essential Hypertension*, will enroll 70–100 participants with pre-hypertension or Stage 1 hypertension. The study uses a two-phase, randomized, sham-controlled design to assess EECP’s potential effects on blood pressure, positioning it as a non-invasive therapy for cardiovascular health. The trial, led by Dr. Lam Yat Yin—Chairman of Centre Medical Group and Director of Hong Kong Asia Heart Centre—aims to validate EECP’s applicability in early-stage hypertension management. UTGL emphasizes the study’s role in advancing evidence-based research for healthy longevity and regenerative technologies, though it does not claim proven efficacy for EECP. The company views blood pressure as a key indicator for early health signals, aligning with its corporate vision of supporting medical innovation. UTGL’s donation reflects its commitment to local medical research and public health initiatives. Mr. Benjamin Leung, CEO of UTGL, and Mr. Derrick Wong, Managing Director, represented the company in supporting the research. UTGL, a licensed global private trust services specialist, frames health and well-being as critical to long-term value, alongside wealth preservation. The study’s findings could provide scientific insights into preventive medicine and cardiovascular risk management. UTGL plans to continue funding research and community health initiatives, guided by professionalism and long-term perspectives. The trial underscores UTGL’s focus on bridging clinical research with public health goals, particularly in anti-aging and chronic disease prevention.